{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:28:26Z","timestamp":1793384906831,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.msard.2016.07.015","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T15:28:33Z","timestamp":1470410913000},"page":"158-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature"],"prefix":"10.1016","volume":"9","author":[{"given":"Elena","family":"Grebenciucova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline T.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2016.07.015_bib1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaneurol.2015.1746","article-title":"Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod","volume":"72","author":"Achtnichts","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2016.07.015_bib2","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.174.10.6346","article-title":"Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis","volume":"174","author":"Arora","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2016.07.015_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2016.07.015_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy off ingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2016.07.015_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2016.07.015_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. The first Phase III clinical study comparing fingolimod with IFN-\u03b21a in relapsing MS","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.msard.2016.07.015_bib7","first-page":"164","article-title":"Cryptococcus neoformans: tripping on Acid in the Phagolysosome","volume":"17","author":"DeLeon-Rodriguez","year":"2016","journal-title":"Front Micro."},{"issue":"11","key":"10.1016\/j.msard.2016.07.015_bib8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul","year":"2016","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.msard.2016.07.015_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2010.02.005","article-title":"Thymic involution and proliferative T-cell responses in multiple sclerosis","volume":"221","author":"Duszczyszyn","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2016.07.015_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2567.1996.d01-689.x","article-title":"Expansion of cytotoxic CD8+ CD28\u2013 T cells in healthy ageing people, including centenarians","volume":"4","author":"Fagnoni","year":"1996","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2016.07.015_bib11","unstructured":"Fingolimod prescribing information, 2016. Fingolimod prescribing information. Available from: \u3008\u3008http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf\u3009\u3009"},{"key":"10.1016\/j.msard.2016.07.015_bib12","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.4049\/jimmunol.142.9.3219","article-title":"Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans","volume":"142","author":"Flesch","year":"1989","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2016.07.015_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2016.07.015_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2016.07.015_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.coi.2009.06.001","article-title":"Effects of aging on B cell function","volume":"4","author":"Frasca","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2016.07.015_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000328005","article-title":"Immunosenescence of human natural killer cells","volume":"3","author":"Gayoso","year":"2011","journal-title":"J. Innate Immun."},{"issue":"5","key":"10.1016\/j.msard.2016.07.015_bib17","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1542\/peds.107.5.e66","article-title":"Serologic evidence for Cryptococcus neoformans infection in early childhood","volume":"107","author":"Goldman","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.msard.2016.07.015_bib18","first-page":"461304","article-title":"Multiple Sclerosis: A Disorder of Altered T-Cell Homeostasis","author":"Haegert","year":"2011","journal-title":"Mult. Scler. Int."},{"issue":"12","key":"10.1016\/j.msard.2016.07.015_bib19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/cid\/cir723","article-title":"Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen","volume":"53","author":"Harris","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.msard.2016.07.015_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.0000000000001929","article-title":"Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod","volume":"85","author":"Huang","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2016.07.015_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4049\/jimmunol.171.1.432","article-title":"Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis","volume":"171","author":"Hug","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib23","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1128\/IAI.01232-08","article-title":"Cryptococcus neoformans directly stimulates perforin production and re- arms NK cells for enhanced anticryptococcal microbicidal activity","volume":"77","author":"Islam","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.msard.2016.07.015_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4049\/jimmunol.1003823","article-title":"Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720- treated multiple sclerosis patients","volume":"187","author":"Johnson","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. A 2\u2013year Phase III clinical study comparing fingolimod with placebo in relapsing MS","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2016.07.015_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1348-0421.1995.tb02180.x","article-title":"T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: involvement of IFN-gamma and its protective effect against cryptococcal infection","volume":"39","author":"Kawakami","year":"1995","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib27","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1128\/IAI.69.11.6643-6650.2001","article-title":"Enhanced gamma interferon production through activation of V\u25a114 natural killer T cells by -galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis","volume":"69","author":"Kawakami","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.msard.2016.07.015_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/eji.200737142","article-title":"Requirement of secondary lymphoid tissues for the induction of primary and secondary T-cell responses against Listeria monocytogenes","volume":"38","author":"Kursar","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib29","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.4049\/jimmunol.173.5.3357","article-title":"NK cells use perforin rather than granulysin for anticrypto- coccal activity","volume":"173","author":"Ma","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12974-015-0460-z","article-title":"Gopal Murugian et al. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 up regulation","volume":"12","author":"Mazzola","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2016.07.015_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.coi.2009.05.023","article-title":"Immunosenescence: what does it mean to health outcomes in older adults?","volume":"4","author":"McElhaney","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib32","first-page":"A372","article-title":"Cellular and humoral influenza vaccine-specific immune responses in patients with multiple sclerosis treated with FTY720 or interferon-\u03b2","volume":"74","author":"Mehling","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2016.07.015_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/sji.12347","article-title":"Tissue distribution dynamics of human NK cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade","volume":"82","author":"Mehling","year":"2015","journal-title":"Scand. J. Immunol."},{"issue":"16","key":"10.1016\/j.msard.2016.07.015_bib34","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"14","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2016.07.015_bib35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/CMR.8.4.515","article-title":"Cryptococcosis in the era of AIDS\u2014100 years after the discovery of Cryptococcus neoformans","volume":"8","author":"Mitchell","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.msard.2016.07.015_bib36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/IAI.01477-13","article-title":"Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production","volume":"82","author":"Murdock","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.msard.2016.07.015_bib37","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1128\/IAI.71.3.1538-1547.2003","article-title":"Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production","volume":"71","author":"Noverr","year":"2003","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.msard.2016.07.015_bib38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/322597","article-title":"Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy","volume":"1","author":"Pappas","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.msard.2016.07.015_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.maturitas.2015.05.004","article-title":"Immunosenescence: Implications for response to infection and vaccination in older people","volume":"82","author":"Pera","year":"2015","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.msard.2016.07.015_bib40","doi-asserted-by":"crossref","first-page":"e56269","DOI":"10.1371\/journal.pone.0056269","article-title":"Epidemiology of cryptococcal meningitis in the US: 1997\u20132009","volume":"8","author":"Pyrgos","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.msard.2016.07.015_bib41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.18632\/aging.100894","article-title":"Aging of immune system: immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults","volume":"8","author":"Qin","year":"2016","journal-title":"Aging"},{"issue":"12","key":"10.1016\/j.msard.2016.07.015_bib42","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1128\/CVI.00242-07","article-title":"Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients","volume":"14","author":"Saha","year":"2007","journal-title":"Clin. Vaccin. Immunol."},{"issue":"16","key":"10.1016\/j.msard.2016.07.015_bib43","article-title":"Treatment, Safety, and Tolerance: Longterm Fingolimod Treatment of Multiple Sclerosis Induces Phenotypical Immunsenescence","volume":"86","author":"Schwanitz","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2016.07.015_bib44","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s11481-013-9465-5","article-title":"Fingolimod modulates peripheral effector and regulatory T cells in MS patients","volume":"8","author":"Serpero","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.msard.2016.07.015_bib45","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.174.3.1746","article-title":"Interferon-\u03b3 at the site of infection determines rate of clearance of infection in cryptococcal meningitis","volume":"174","author":"Siddiqui","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coi.2014.04.002","article-title":"Shaping of NK cell subsets by aging","volume":"29C","author":"Solana","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.msard.2016.07.015_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.smim.2012.04.008","article-title":"Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans","volume":"24","author":"Solana","year":"2012","journal-title":"Semin Immunol."},{"issue":"8","key":"10.1016\/j.msard.2016.07.015_bib48","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0047-6374(02)00035-0","article-title":"Immunological memory and late onset autoimmunity","volume":"123","author":"Stacy","year":"2002","journal-title":"Mech. Ageing Dev."},{"issue":"1\u20132","key":"10.1016\/j.msard.2016.07.015_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2014.03.007","article-title":"Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab","volume":"340","author":"Valenzuela","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2016.07.015_bib50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.0105-2896.2005.00256.x","article-title":"CD28 extinction in human T cells: altered functions and the program of T-cell senescence","author":"Vallejo","year":"2005","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.msard.2016.07.015_bib51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/EC.00039-10","article-title":"Cryptococcal interactions with the host immune system","volume":"9","author":"Voelz","year":"2010","journal-title":"Eukaryot. Cell"},{"issue":"5","key":"10.1016\/j.msard.2016.07.015_bib52","article-title":"Cryptococcal meningitis after discontinuation of fingolimod in a patient with multiple sclerosis","author":"Ward","year":"2016","journal-title":"Mult. Scler. Rel Dis."},{"key":"10.1016\/j.msard.2016.07.015_bib53","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/gerona\/60.5.556","article-title":"An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans","volume":"5","author":"Wikby","year":"2005","journal-title":"J. Gerontol. A Biol. Sci. Med Sci."},{"issue":"3","key":"10.1016\/j.msard.2016.07.015_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"Williamson","year":"2015","journal-title":"CNS Drugs"}],"updated-by":[{"DOI":"10.1016\/j.msard.2016.09.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816301250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816301250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:39:11Z","timestamp":1761899951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034816301250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":53,"alternative-id":["S2211034816301250"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2016.07.015","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2016.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}